LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real--World Evidence, Long--Term Outcomes and Patient Experience Across Multiple Dermatological Conditions

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) ...

Bristol Myers wins FDA approval for Opdivo in first-line Hodgkin lymphoma

Bristol Myers Squibb (BMY) stock is in focus as the FDA expands the label for cancer drug Opdivo as a first-line therapy for Hodgkin lymphoma. Read more here.

Home-based chemotherapy: Pilot study demonstrates safety and feasibility

In a study published in NEJM Catalyst, Mayo Clinic researchers demonstrate that chemotherapy can be safely delivered in patients' homes. The study evaluated Mayo Clinic's Cancer CARE Beyond Walls ...

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ...
BioPharma Dive

Roche stops work on experimental SMA drug

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.

Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China

Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special ...

Nanoparticle discovery could unlock universal immunotherapy for cancer

T cells are supposed to be relentless. These white blood cells patrol the body, identify threats, and destroy them.

Tenax Therapeutics: A Binary Bet With Heavy Downside Likely

Tenax Therapeutics is a "Sell" given its negative risk/reward skew even under bullish scenarios. Here's what investors need to know about TENX stock.